« A disruptive technology, which can be applied in the treatment of numerous conditions »

Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to
evaluate Batten-1 in CLN3 Batten disease

09/05/2023 7.30 AM CET

Download PDF File (<1Mo)

THERANEXUS publishes its 2022 full-year results and presents an update on its programs

12/04/2023 6PM CET

Download PDF File (<1Mo)

Information on the number of shares composing share capital

04/04/2023
Download PDF File (276Ko)

THERANEXUS, BBDF and Cardiff University present their novel research on Batten-1 and Batten disease at Worldsymposium 2023

20/02/2023 6PM CET

Download PDF File (<1Mo)

AISTROSIGHT: New joint project team between Theranexus, INRIA, Claude Bernard University Lyon 1 and Hospices Civils de Lyon targeting rare neurological diseases

10/02/2023 before market opens

Download PDF File (<1Mo)

THERANEXUS publishes its cash position as of 31 December 2022 and announces organizational changes

18/01/2023 before market opens

Download PDF File (<1Mo)

New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)

05/01/2023

Download PDF File (<1Mo)